65.39

3.76% 2.37

After Hours: 65.32 -0.07 -0.11%

Anaptysbio Inc (ANAB)

Overview News Price History Option Chain Financials Discussions Forecast

Anaptysbio Inc stock is traded at $65.39, with a volume of 284.02K. It is up +3.76% in the last 24 hours and up +18.65% over the past month. AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Previous Close:

$63.02

Open:

$64.06

24h Volume:

284.02K

Relative Volume:

0.56

Market Cap:

$1.88B

Revenue:

$234.60M

Net Income/Loss:

$-13.23M

P/E Ratio:

-125.61

EPS:

-0.5206

Net Cash Flow:

$19.61M

1W Performance:

+1.04%

1M Performance:

+18.65%

6M Performance:

+196.69%

1Y Performance:

+254.61%

1-Day Range:

$64.00

$66.01

1-Week Range:

$60.92

$66.01

52-Week Range:

$15.40

$68.39

Anaptysbio Inc Stock (ANAB) Company Profile

Name

Anaptysbio Inc

Sector

Healthcare (1114)

Industry

Biotechnology (623)

Phone

858-362-6295

Address

10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA

Employee

104

Twitter

@anaptysbio

Next Earnings Date

2024-11-08

Latest SEC Filings

ANAB's Discussions on Twitter

Compare ANAB vs VRTX, REGN, ALNY, ARGX, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ANAB Anaptysbio Inc	65.39	1.81B	234.60M	-13.23M	19.61M	-0.5206
VRTX Vertex Pharmaceuticals Inc	454.97	113.96B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	749.47	78.41B	14.34B	4.50B	3.77B	41.56
ALNY Alnylam Pharmaceuticals Inc	328.70	40.85B	3.71B	313.75M	465.38M	2.2571
ARGX Argen X Se Adr	697.05	42.05B	4.16B	1.29B	734.26M	19.58
INSM Insmed Inc	148.31	29.99B	606.42M	-1.28B	-997.58M	-6.403

Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-07-26	Resumed	UBS	Buy
Oct-13-25	Initiated	Barclays	Overweight
Jun-04-25	Upgrade	H.C. Wainwright	Neutral → Buy
Feb-04-25	Initiated	Wolfe Research	Outperform
Dec-11-24	Downgrade	H.C. Wainwright	Buy → Neutral
Dec-02-24	Downgrade	BTIG Research	Buy → Neutral
Jul-22-24	Initiated	H.C. Wainwright	Buy
Jul-19-24	Upgrade	JP Morgan	Neutral → Overweight
Apr-16-24	Initiated	Leerink Partners	Outperform
Apr-11-24	Initiated	Wells Fargo	Overweight
Mar-12-24	Upgrade	Wedbush	Neutral → Outperform
Feb-26-24	Initiated	BTIG Research	Buy
Feb-21-24	Initiated	Stifel	Buy
Feb-16-24	Initiated	Piper Sandler	Overweight
May-22-23	Upgrade	JP Morgan	Underweight → Neutral
May-18-23	Initiated	TD Cowen	Outperform
Jan-06-23	Downgrade	Raymond James	Outperform → Mkt Perform
Nov-01-22	Upgrade	Guggenheim	Neutral → Buy
Sep-19-22	Resumed	H.C. Wainwright	Buy
Sep-13-22	Downgrade	Truist	Buy → Hold
Sep-01-22	Initiated	Raymond James	Outperform
Mar-22-22	Downgrade	Guggenheim	Buy → Neutral
Jun-22-21	Initiated	H.C. Wainwright	Buy
May-21-21	Initiated	UBS	Neutral
Mar-16-21	Upgrade	Truist	Hold → Buy
Mar-09-21	Downgrade	Wedbush	Outperform → Neutral
Mar-08-21	Downgrade	JP Morgan	Overweight → Underweight
Feb-11-21	Upgrade	JP Morgan	Underweight → Overweight
Oct-27-20	Upgrade	Wedbush	Neutral → Outperform
Oct-14-20	Upgrade	Guggenheim	Neutral → Buy
Nov-08-19	Downgrade	JP Morgan	Overweight → Underweight
Nov-08-19	Downgrade	Jefferies	Buy → Hold
Nov-08-19	Downgrade	SunTrust	Buy → Hold
Nov-08-19	Downgrade	Wedbush	Outperform → Neutral
Jun-21-19	Downgrade	Credit Suisse	Outperform → Neutral
Jun-21-19	Downgrade	Stifel	Buy → Hold
Dec-20-18	Initiated	H.C. Wainwright	Buy
Nov-21-18	Initiated	JP Morgan	Overweight
Jul-19-18	Initiated	Credit Suisse	Outperform
Apr-04-18	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Mar-27-18	Reiterated	Stifel	Buy
Mar-06-18	Reiterated	Stifel	Buy
Feb-15-18	Reiterated	SunTrust	Buy
Jan-23-18	Reiterated	Credit Suisse	Outperform
Nov-15-17	Initiated	SunTrust	Buy
Nov-09-17	Initiated	Jefferies	Buy
Oct-11-17	Reiterated	RBC Capital Mkts	Outperform
Sep-15-17	Initiated	RBC Capital Mkts	Outperform

View All

Anaptysbio Inc Stock (ANAB) Latest News

Mar 25, 2026

Analysis Recap: Can AnaptysBio Inc grow without external fundingRecession Risk & Weekly High Return Stock Forecasts - baoquankhu1.vn

Mar 25, 2026

Mar 23, 2026

Investment Report: Can AnaptysBio Inc reach all time highs this yearLong Setup & Daily Price Action Insights - baoquankhu1.vn

Mar 23, 2026

Mar 22, 2026

RSI Check: Will AnaptysBio Inc benefit from geopolitical trends2026 Year in Review & Capital Efficient Trade Techniques - baoquankhu1.vn

Mar 22, 2026

AnaptysBio (NASDAQ:ANAB) Sees Unusually-High Trading Volume – Should You Buy? - Defense World

Mar 22, 2026

Mar 20, 2026

ANAB Stock Falls After It Sues GSK Unit Tesaro Again, Claims Fresh Breach Of 2014 Deal - MSN

Mar 20, 2026

Tranche Update on AnaptysBio, Inc.'s Equity Buyback Plan announced on March 24, 2025. - marketscreener.com

Mar 20, 2026

AnaptysBio (NASDAQ:ANAB) Sees Strong Trading VolumeTime to Buy? - MarketBeat

Mar 20, 2026

Mar 18, 2026

Aug Levels: Does AnaptysBio Inc stock have upside surprise potential2026 Recap & Low Drawdown Investment Strategies - baoquankhu1.vn

Mar 18, 2026

ANAB Rating Boost: UBS Raises Price Target to $90 | ANAB Stock N - GuruFocus

Mar 18, 2026

Mar 17, 2026

UBS Group Issues Positive Forecast for AnaptysBio (NASDAQ:ANAB) Stock Price - MarketBeat

Mar 17, 2026

UBS raises AnaptysBio stock price target to $90 on pipeline upside - Investing.com Australia

Mar 17, 2026

UBS raises AnaptysBio stock price target to $90 on pipeline upside By Investing.com - Investing.com South Africa

Mar 17, 2026